SARS-CoV-2 (COVID-19) Nucleocapsid Antibody

Contact us
ProSci
Product Code: PSI-9099
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-9099-0.02mg0.02mg£150.00
Quantity:
PSI-9099-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Western Blot (WB)
Storage:
SARS-CoV-2 (COVID-19) Nucleocapsid antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 6
<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient (Sun et al., 2020)</strong><br> Detection of SARS-CoV-2 nucleocapsid protein by anti-SARS-COV-2 nucleocapsid antibodies (9099, 0.02 μg/mL, A,B) or SARS-CoV-2 Spike S1 antibodies (9083, 1 μg/mL D,E) in adjacent sections of autopsy lung tissue from COVID-19 deceased patient. Negative control staining on autopsy lung tissue from patient who died from non-COVID-19 pneumonia is shown for Nucleocapsid protein (C) or Spike protein (F). Negative control using normal rabbit immunoglobulin on COVID-19 autopsy tissue is presented (G). DAB chromogen and hematoxylin counterstain are used. Scale bars: 50uM in A, C, D, F, G; 20μM in B and E.
2 / 6
<strong>Figure 2 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (9099, 0.02 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 40X magnification)
3 / 6
<strong>Figure 3 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (9099, 0.02 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 63X magnification)
4 / 6
<strong>Figure 4 Western Blot Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein</strong><br>Loading: 50 ng per lane of SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein. Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid, 9099, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.5 μg/mL, Lane 2: 1 μg/mL and Lane 3: 2 μg/mL.
5 / 6
<strong>Figure 5 ELISA Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein</strong><br>Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid antibody, 9099 (1 μg/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein as coating antigen and the anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000ng/mL.
6 / 6
<strong>Figure 6 ELISA Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein</strong><br>Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid antibody, 9099 (1 μg/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein (10-306) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000ng/mL.
❮❯

<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient (Sun et al., 2020)</strong><br> Detection of SARS-CoV-2 nucleocapsid protein by anti-SARS-COV-2 nucleocapsid antibodies (9099, 0.02 μg/mL, A,B) or SARS-CoV-2 Spike S1 antibodies (9083, 1 μg/mL D,E) in adjacent sections of autopsy lung tissue from COVID-19 deceased patient. Negative control staining on autopsy lung tissue from patient who died from non-COVID-19 pneumonia is shown for Nucleocapsid protein (C) or Spike protein (F). Negative control using normal rabbit immunoglobulin on COVID-19 autopsy tissue is presented (G). DAB chromogen and hematoxylin counterstain are used. Scale bars: 50uM in A, C, D, F, G; 20μM in B and E.
<strong>Figure 2 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (9099, 0.02 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 40X magnification)
<strong>Figure 3 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (9099, 0.02 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 63X magnification)
<strong>Figure 4 Western Blot Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein</strong><br>Loading: 50 ng per lane of SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein. Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid, 9099, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.5 μg/mL, Lane 2: 1 μg/mL and Lane 3: 2 μg/mL.
<strong>Figure 5 ELISA Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein</strong><br>Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid antibody, 9099 (1 μg/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein as coating antigen and the anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000ng/mL.
<strong>Figure 6 ELISA Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein</strong><br>Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid antibody, 9099 (1 μg/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein (10-306) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000ng/mL.

Documents

Further Information

Additional Names:
SARS-CoV-2 (COVID-19) Nucleocapsid antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Nucleocapsid protein, N protein, Nucleocapsid Phosphoprotein
Application Note:
WB: 0.5-2 μg/mL

SARS-CoV-2 (COVID-19) Nucleocapsid antibody can be used for the detection of SARS-CoV-2 (COVID-19) Nucleocapsid protein in ELISA. It will detect 4 ng of free peptide at 1 μg/mL. All other applications and species not yet tested.
Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019?20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells?(4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).
Background References:
  • Zhu et al. N Engl J Med.?2020 Feb 20;382(8):727-733.
  • Kiyotani et al. J Hum Genet.?2020 Jul;65(7):569-575.
  • Chang et al. J Biomed Sci.?2006 Jan;13(1):59-72.
  • Cui et al. J Virol.?2015 Sep;89(17):9029-43.
  • Chen et al. Eur J Clin Microbiol Infect Dis.?2005 Aug;24(8):549-53.
  • Emerg Infect Dis.?2004 Sep;10(9):1558-62.
Buffer:
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted reactivity based on immunogen sequence: SARS-CoV Nucleocapsid proteins: (100%)
Immunogen:
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (9099) was raised against a peptide corresponding to 17 amino acids near the center of SARS-CoV-2 (COVID-19) Nucleocapsid protein.

The immunogen is located within 230-280 amino acids of SARS-CoV-2 (COVID-19) Nucleocapsid protein.
ISOFORMS:
SARS-CoV-2 (COVID-19) Nucleocapsid has one isoform (419aa).
NCBI Gene ID #:
43740575
NCBI Official Name:
Nucleocapsid Phosphoprotein
NCBI Official Symbol:
N
NCBI Organism:
SARS-CoV-2
Physical State:
Liquid
Protein Accession #:
QHD43423
Protein GI Number:
1820552696
Purification:
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody is affinity chromatography purified via peptide column.
Research Area:
Infectious Disease,COVID-19
User NOte:
Optimal dilutions for each application to be determined by the researcher.

References

  1. Sun Y, Ge L, Rau MJ, Patton MD, Gallan AJ, Felix JC, Rui H. Sensitive and specific immunohistochemistry protocols for detection of SARS-CoV-2 nucleocapsid and spike proteins in formalin-fixed, paraffin-embedded COVID-19 patient tissues. ProtocolExchange, 16 July 2020; DOI:10.21203/rs.3.pex-1011/v1